Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

NCT01968460 is registered in ClinicalTrials.gov with Pharma Two B Ltd. as lead sponsor.

NCT NCT01968460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01968460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Lead sponsor
Pharma Two B Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
December 31, 2013
Completion date
June 30, 2015
Enrollment
149 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease